secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2025-09-12T23:59:59+00:00
Accession:  0001193125-25-202307
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes sues Teva, Apotex, MSN over LYBALVI patents; enters VIVITROL AG deal with Amneal
--------------------------------------------------------------------------------

- Filed patent lawsuits against Teva (8/15), Apotex (8/27), MSN (9/5) over generic LYBALVI; 30-month FDA stays triggered.
- LYBALVI patents expiring 2032-2041; lawsuit amended 8/20 to include additional patent.
- Entered authorized generic supply agreement with Amneal for VIVITROL, effective upon third-party ANDA launch.
- Amneal may distribute AG VIVITROL for one year, supply limited to ~15% of 2024 unit sales; profit sharing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000119312525202307/0001193125-25-202307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000119312525202307/alks-20250815.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-202307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer